Model based on GRID-derived descriptors for estimating CYP3A4 enzyme stability of potential drug candidates
暂无分享,去创建一个
Ismael Zamora | Patrizia Crivori | Italo Poggesi | Christian Orrenius | Bill Speed | I. Zamora | I. Poggesi | P. Crivori | C. Orrenius | Bill Speed
[1] M Pastor,et al. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[2] D A Smith,et al. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics , 1996, Medicinal research reviews.
[3] P. Carrupt,et al. Molecular fields in quantitative structure–permeation relationships: the VolSurf approach , 2000 .
[4] A. Berglund,et al. Structure-property model for membrane partitioning of oligopeptides. , 2000, Journal of medicinal chemistry.
[5] Barry C. Jones,et al. Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics , 1997 .
[6] Ajay,et al. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.
[7] H. Kubinyi,et al. A scoring scheme for discriminating between drugs and nondrugs. , 1998, Journal of medicinal chemistry.
[8] H. van de Waterbeemd,et al. Property-based design: optimization of drug absorption and pharmacokinetics. , 2001, Journal of medicinal chemistry.
[9] P. Goodford. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.
[10] D. Lewis,et al. The CYP2 family: models, mutants and interactions. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.
[11] S. Wold,et al. Multivariate Data Analysis in Chemistry , 1984 .
[12] R. Sheridan,et al. A model for predicting likely sites of CYP3A4-mediated metabolism on drug-like molecules. , 2003, Journal of medicinal chemistry.
[13] Panos Macheras,et al. In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. , 2002, European Journal of Pharmaceutical Sciences.
[14] M H Tarbit,et al. Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.
[15] B Testa,et al. Predicting blood-brain barrier permeation from three-dimensional molecular structure. , 2000, Journal of medicinal chemistry.
[16] Paul Geladi,et al. Principal Component Analysis , 1987, Comprehensive Chemometrics.
[17] A. Tropsha,et al. Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. , 2003, Journal of medicinal chemistry.
[18] S. Pickett,et al. GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. , 2000, Journal of medicinal chemistry.
[19] Gabriele Cruciani,et al. Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. , 2003, Journal of medicinal chemistry.
[20] Mika A. Kastenholz,et al. GRID/CPCA: a new computational tool to design selective ligands. , 2000, Journal of medicinal chemistry.
[21] P. Watkins,et al. THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS* , 2000, Drug metabolism reviews.
[22] F. Guengerich,et al. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. , 2001, Chemical research in toxicology.